A detailed history of Assenagon Asset Management S.A. transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 353,837 shares of PMVP stock, worth $569,677. This represents 0.0% of its overall portfolio holdings.

Number of Shares
353,837
Previous 260,028 36.08%
Holding current value
$569,677
Previous $421,000 25.18%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$1.44 - $1.69 $135,084 - $158,537
93,809 Added 36.08%
353,837 $527,000
Q2 2024

Jul 18, 2024

BUY
$1.51 - $2.21 $285,713 - $418,162
189,214 Added 267.2%
260,028 $421,000
Q4 2023

Jan 17, 2024

SELL
$1.23 - $6.6 $230,900 - $1.24 Million
-187,724 Reduced 72.61%
70,814 $219,000
Q3 2023

Nov 06, 2023

SELL
$6.01 - $8.93 $975,338 - $1.45 Million
-162,286 Reduced 38.56%
258,538 $1.59 Million
Q1 2023

Apr 18, 2023

SELL
$4.77 - $9.16 $97,684 - $187,587
-20,479 Reduced 4.64%
420,824 $2.01 Million
Q4 2022

Jan 12, 2023

SELL
$8.17 - $12.95 $180,091 - $285,456
-22,043 Reduced 4.76%
441,303 $3.84 Million
Q3 2022

Oct 27, 2022

SELL
$11.4 - $17.18 $1.89 Million - $2.86 Million
-166,193 Reduced 26.4%
463,346 $5.51 Million
Q2 2022

Jul 27, 2022

SELL
$9.23 - $22.43 $78,685 - $191,215
-8,525 Reduced 1.34%
629,539 $8.97 Million
Q1 2022

Apr 25, 2022

BUY
$14.86 - $23.55 $7.92 Million - $12.6 Million
532,980 Added 507.19%
638,064 $13.3 Million
Q4 2021

Feb 01, 2022

BUY
$19.99 - $30.24 $961,998 - $1.46 Million
48,124 Added 84.49%
105,084 $2.43 Million
Q3 2021

Oct 19, 2021

SELL
$26.84 - $36.58 $2.89 Million - $3.93 Million
-107,526 Reduced 65.37%
56,960 $1.7 Million
Q2 2021

Jul 15, 2021

BUY
$28.01 - $36.01 $4.61 Million - $5.92 Million
164,486 New
164,486 $5.62 Million

Others Institutions Holding PMVP

About PMV Pharmaceuticals, Inc.


  • Ticker PMVP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,622,600
  • Market Cap $73.5M
  • Description
  • PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...
More about PMVP
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.